Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway
BackgroundThe Food and Drug Administration has approved the Serine/threonine-protein kinase B-raf (BRAF) inhibitor and Mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor combo as the first-line treatment for individuals with metastatic melanoma, although the majority of these pa...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-01-01
|
| Colección: | Frontiers in Oncology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1429018/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|